Bioxytran (BIXT) Cash & Equivalents (2011 - 2026)
Bioxytran (BIXT) posted Cash & Equivalents of $463047.0 for Q1 2026, down 9.19% sequentially from $509914.0 in Q4 2025, and up 10549.66% YoY from N/an in Q1 2025.
Bioxytran (BIXT) Cash & Equivalents (2011 - 2026) Analysis & Trends
Bioxytran has reported Cash & Equivalents for 16 years, with the latest figure at $463047.0 in Q1 2026.
- Quarterly Cash & Equivalents rose 10549.66% year-over-year to $463047.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $463047.0 (up 10549.66% YoY) and the FY2025 annual result came in at $509914.0, up 9793.56% from the prior year.
- Cash & Equivalents slipped to $463047.0 in Q1 2026 per BIXT's latest filing, from $509914.0 in the prior quarter.
- Over five years, Cash & Equivalents peaked at $739584.0 in Q1 2022 and troughed at $3144.0 in Q2 2025.
- A 5-year average of $192559.8 and a median of $45181.0 in 2023 frame the typical range for Cash & Equivalents.
- The sharpest annual moves came in 2024 and 2026: Cash & Equivalents sank 93.48% in 2024, then soared 10549.66% in 2026.
- Over 5 years, Cash & Equivalents stood at $295401.0 in 2022, then sank by 91.17% to $26086.0 in 2023, then plunged by 80.24% to $5154.0 in 2024, then soared by 9793.56% to $509914.0 in 2025, then retreated by 9.19% to $463047.0 in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $463047.0, $509914.0, and $14499.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.72 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.71 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.93 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 544.80 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 811.99 Mn |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - | 250,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 463,047.00 |
| Dec 31, 2025 | 509,914.00 |
| Sep 30, 2025 | 14,499.00 |
| Jun 30, 2025 | 3,144.00 |
| Mar 31, 2025 | 4,348.00 |
| Dec 31, 2024 | 5,154.00 |
| Sep 30, 2024 | 34,672.00 |
| Jun 30, 2024 | 13,522.00 |
| Mar 31, 2024 | 10,024.00 |
| Dec 31, 2023 | 26,086.00 |
| Sep 30, 2023 | 80,273.00 |
| Jun 30, 2023 | 45,181.00 |
| Mar 31, 2023 | 153,801.00 |
| Dec 31, 2022 | 295,401.00 |
| Sep 30, 2022 | 374,190.00 |
| Jun 30, 2022 | 500,677.00 |
| Mar 31, 2022 | 739,584.00 |
| Dec 31, 2021 | 72,358.00 |
| Sep 30, 2021 | 243,994.00 |
| Jun 30, 2021 | 388,043.00 |